/PRNewswire/ Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen s oncology research and.
In immune checkpoint inhibitor trials, time to deterioration of physical function appears to be a better surrogate for overall survival than progression-free survival, new data suggest.
The companies aiming to beat cancer serve up the highlights in the June quarter proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.